TWI311562B - One step rapid desalting and protein refolding process - Google Patents

One step rapid desalting and protein refolding process Download PDF

Info

Publication number
TWI311562B
TWI311562B TW95116399A TW95116399A TWI311562B TW I311562 B TWI311562 B TW I311562B TW 95116399 A TW95116399 A TW 95116399A TW 95116399 A TW95116399 A TW 95116399A TW I311562 B TWI311562 B TW I311562B
Authority
TW
Taiwan
Prior art keywords
protein
solution
centrifugation
denatured
column
Prior art date
Application number
TW95116399A
Other languages
Chinese (zh)
Other versions
TW200742744A (en
Inventor
Kou-Juey Wu
Chi-Hung Huang
Original Assignee
Northern Taiwan Bio Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northern Taiwan Bio Pharm Inc filed Critical Northern Taiwan Bio Pharm Inc
Priority to TW95116399A priority Critical patent/TWI311562B/en
Publication of TW200742744A publication Critical patent/TW200742744A/en
Application granted granted Critical
Publication of TWI311562B publication Critical patent/TWI311562B/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Description

•1311562 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種用於蛋白質純化過程中 之新穎單步驟蛋白去鹽與折疊方法,其有別於傳 統之層析管柱方法’而係在蛋白以變性條件大量 純化後’藉由通過蛋白濃縮管柱或蛋白超濾膜, 在高度疏水分子保護下除去變性鹽類,並^去鹽 過程中保持蛋白於變性條件下’再藉由除去高^ 疏水分子的過程,以控制蛋白的再折疊。 【先前技術】 在後基因體時代’蛋白質體學開始崛起,關 於蛋白質結構與功能之研究.備受重視。目前許多 關於蛋白結構的解析計晝已在各國展開,當中有 許多重要的目標蛋白需要被大量的表現,並且取 得具有生理活性的蛋白(參見,S. Yokoyama,Cwrr. Opin. Chem. Biol 2003 ; 7(1), 39-43 ) ° ^ ^ 生技製藥產業高度發展的今日,許多的重組蛋白 ❿藥物需求日增,以上蛋白由於原核表現系統的成 熟、容易操作與低成本,目前許多蛋白都藉由藉 由原核的表現系統來大量取得。 然而’原核表現系統雖可用於快速並大量獲 得蛋白質’卻常發生其所表現後的蛋白為不可溶 體(inclusion body )的情況,這是由於原核細胞 並不如同真核糸統中,具有熱休克蛋白(Heat shock protein)或護衛蛋白(Chaperon)來協助 蛋白折疊。在實驗室或工章制短上,為解決此一 缺點,遂常藉由先利用蛋白變性方法\ deI;atureBACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel single-step protein desalination and folding method for protein purification, which is different from the conventional chromatography column method. After the protein is purified in large quantities under denaturing conditions, 'by removing the denatured salt under the protection of highly hydrophobic molecules through the protein concentrating column or protein ultrafiltration membrane, and keeping the protein under denaturing conditions during the salt removal process' The process of high ^ hydrophobic molecules to control the refolding of proteins. [Prior Art] In the post-genome era, proteomics began to rise, and research on protein structure and function has received much attention. At present, many analytical methods for protein structure have been carried out in various countries, and many important target proteins need to be expressed in large quantities and obtain physiologically active proteins (see, S. Yokoyama, Cwrr. Opin. Chem. Biol 2003; 7(1), 39-43 ) ° ^ ^ The biotechnology pharmaceutical industry is highly developed today, and many recombinant protein ❿ drugs are in increasing demand. Due to the maturity, easy operation and low cost of the prokaryotic expression system, many proteins are currently available. It is obtained in large quantities by the prokaryotic performance system. However, 'the prokaryotic expression system can be used to obtain proteins quickly and in large quantities,' but often the protein after its expression is an inclusion body, because prokaryotic cells are not as hot as eukaryotic systems. Heat shock protein or Chaperon to assist in protein folding. In order to solve this shortcoming in the laboratory or the short workmanship, it is often used to first utilize the protein denaturation method\deI;

5 TBH03-P060009-TW 1311562 condition)將蛋白變性,以達到可溶的目的。而 後,再藉由除去變性條件,重新賦予蛋白正常生 理構形與活性。 傳統上,蛋白質去鹽與再折疊(Pr〇tein desalting and refolding)可藉由下列幾種方式: 1.緩慢透析法(slow dialysis method)、2.稀釋法 (dilution method)、或3.小分子篩量的去鹽管柱 (desalting column )來達成(請參見,例如, Natalia 等人,On column chemical refolding of protein Pharmagenomics (2004) pp.22-26 ) ° 然 ⑩ 而上述幾種方法各有其缺點,例如對於緩慢透析 法而言,如果目標蛋白具有不穩定特性,則由於 缓慢透析法需要長時間透析,故會造成蛋白降解 (protein degradation )。而」稀釋法對於具有多量 疏水區(Hydrophobic domain) 的蛋白質,則會 造成蛋白沈積(insoluble aggregation);或對於 鹽敏感蛋白質(salt sensitively),則會造成因離 子濃度快速改變’而發生的蛋白質降解(protein degradation ) ° • 因此,目前對於較不穩定且鹽敏感之蛋白 質,多使用管柱層析法進行去鹽與再折疊。對於 蛋白量的提局’管柱層析去鹽法若直接藉由更換 較大管柱來達成’則需要高量的沖提緩衝液 (elution buffer),同時,更長的管柱也代表更 長的操作時間。然而’矣鹽管柱在製程放大上最 主要的問題係在於’兩倍放大體積的管柱,並不 等同於兩倍蛋白純化能力。而對某些必須維持在 蛋白變性狀態的蛋白質而言,去鹽管柱的快速去 鹽又會造成因蛋白質對離子強度敏感,而使蛋白5 TBH03-P060009-TW 1311562 condition) Denature the protein to achieve solubility. The normal physiological configuration and activity of the protein is then re-assigned by removing the denaturing conditions. Traditionally, Pr去tein desalting and refolding can be performed in several ways: 1. slow dialysis method, 2. dilution method, or 3. small molecular sieve The amount of desalting column is achieved (see, for example, Natalia et al., On column chemical refolding of protein Pharmagenomics (2004) pp. 22-26). However, the above several methods each have their disadvantages. For example, for the slow dialysis method, if the target protein has an unstable property, protein degradation is caused because the slow dialysis method requires long-time dialysis. "Dilution method can cause insoluble aggregation for proteins with a large number of Hydrophobic domains; or protein degradation due to rapid changes in ion concentration for salt sensitively." (protein degradation) ° • Therefore, for less stable and salt-sensitive proteins, column chromatography is often used for desalting and refolding. For the promotion of the amount of protein, if the tube column chromatography method is used to directly replace the larger column, a high amount of elution buffer is required, and the longer column also represents more. Long operating time. However, the most important problem with the 矣 salt column in process amplification is the column of twice the enlarged volume, which is not equivalent to twice the protein purification capacity. For some proteins that must be maintained in the denatured state of the protein, the rapid desalting of the desalted column causes the protein to be sensitive to ionic strength and the protein

6 TBH03-P060009-TW 1311562 質在去鹽過程中發生的降解。為此,必須發展— 種能使蛋白維持在接近變性構形,並且^ 2二 的大量操作方法。 & 先前文獻報導(D. R0zema and S.H GeUm 35(49),1 5760-1 577 1 ),一種利 水性物質模仿真核護衛蛋白,來防止蛋白 ^ 蛋白變性過程中,發生不溶性的沈積, = 水性物質來令蛋白折疊的方法,此種 t ^ Τ 工的濩衛蛋白折疊法 (arHf..〗 , · v artificial chaperone-assisted refolding)。此類方半 成功地令蛋白不需藉助層析管柱去鹽去二$ 疊’卻仍需要較長的進行時間,而且^ * 與過濾過程中造成蛋白損失。因此,本: 於刖述之人工的護衛蛋白拆疊法,發展^ 一 二 用蛋白濃縮管柱(centric〇n )或蛋白超 cel.l )進行快速去鹽與蛋白質再折疊的=法。s ir 【發明内容】 目的及優點將部分描逑於下 易見。 目的係提供,一種新穎單步 法’其特徵在於將所欲蛋白 =後,藉由通過蛋白濃縮管 南度疏水性(hydrophobic ) 鹽類(如尿素),並在去鹽 性條件下’再藉由除去高度 制蛋白的再折疊。 明目的’具有本發明特徵之 匕含.(1)將經大量純化含 或可 驟蛋白 質以變 柱或蛋 分子保 過程中 疏水分 蛋白去 有所欲 本發明之 由描述中顯而 本發明之 去鹽與折疊方 性條件大量純 白超遽膜,在 護下除去變性 保持蛋白於變 子的過程,控 根據本發 鹽與折疊方法6 TBH03-P060009-TW 1311562 Degradation of the quality during desalting. To this end, it is necessary to develop a number of methods of operation that maintain the protein in a manner close to the denatured configuration. & Previous literature reports (D. R0zema and SH GeUm 35(49), 1 5760-1 577 1 ), a water-based substance model that simulates nuclear protective proteins to prevent insoluble deposition during protein denaturation. A method in which a water-based substance is used to fold a protein, such a t ^ 濩 濩 蛋白 蛋白 ( ( ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar ar 。 。 。 。 This type of semi-successfully allows the protein to go to the salt column without the aid of a chromatography column, but it still takes a long time to carry out, and the protein is lost during the filtration process. Therefore, this: The artificial defensive protein unfolding method described in the essay, the development of the protein concentrating column (centric 〇n) or protein super cel.l) for rapid desalting and protein refolding = method. s ir [Summary] The purpose and advantages will be partially described below. The objective is to provide a novel single-step method which is characterized by the desired protein = after, by means of a protein concentrating tube south of a hydrophobic salt (such as urea), and under the salt-removing conditions Refolding by removal of highly processed proteins. The invention has the characteristics of the present invention. (1) The invention will be described in the description of the invention by extensive purification of the containing or cleavable protein to change the hydrophobic protein in the column or egg molecule. Desalting and folding of the square conditions, a large number of pure white super-membrane, under the protection of the process of removing the protein from the degeneration, control the salt and folding method according to the present invention

TBH03-P060009-TW 7 1311562 蛋白質之變性溶液與含有高度疏水性分子之溶 液混合;(2)將該混合液通過蛋白濃縮管柱或蛋 白超濾膜;及(3)將經步驟(2)脫鹽之蛋白溶液以 漸進離心置換方式除去該高度疏水分子,而使變 性蛋白再折疊成活性分子。 於本文中,“變性蛋白質”係指因其具有不可 溶性,而需要以變性方式進行大量純化得之蛋白 質。 於本文中,“高度疏水性分子”係指用以於改 變蛋白變性(脫除變性鹽類)過程中,防止所欲 蛋白發生不溶性沈積的疏水性物質,其為該項技 藝中已知,且可利用於本發明之疏水性分子實例 包括(但不限定於),如Natalia等人於”On column chemical refolding of protein Pharmagenomics (2004) pp.22-26n中所記載之疏水性分子,然而, 任何可供使用之疏水性化合物如Triton X-100、 tween_20或多苯環化合物均可以應用於本發明 之方法。 根據本發明,漸進離心置換去除高度疏水分 • 子之條件,係依所欲分離蛋白之種類而有所變 化。於本發明之較佳具體態樣中,對於變性 HOXB4H蛋白,係以約1000〜約2500 g/min離心 速度,經5 _ 1 0次離心逐次置換以由低至高濃度 之諸如環糊精(cyclodextrin)等大分子疏水性物質 之溶液,而將該高度k水分子去除,使變性 HOXB4H蛋白再折疊恢復成天然形式(native form) ° 【實施方式】TBH03-P060009-TW 7 1311562 Protein denaturation solution is mixed with a solution containing highly hydrophobic molecules; (2) the mixture is passed through a protein concentrating column or protein ultrafiltration membrane; and (3) desalted by step (2) The protein solution removes the highly hydrophobic molecule by progressive centrifugal displacement, and the denatured protein is refolded into an active molecule. As used herein, "denatured protein" refers to a protein that requires extensive purification in a denatured manner due to its insolubility. As used herein, "highly hydrophobic molecule" refers to a hydrophobic material that is used in the process of altering protein denaturation (removing denaturing salts) to prevent insoluble deposition of the desired protein, as is known in the art, and Examples of hydrophobic molecules that can be utilized in the present invention include, but are not limited to, hydrophobic molecules as described in Natalia et al., "On column chemical refolding of protein Pharmagenomics (2004) pp. 22-26n, however, any Hydrophobic compounds such as Triton X-100, tween_20 or polyphenylene ring compounds which can be used can be applied to the method of the present invention. According to the present invention, progressive centrifugation replaces the condition of highly hydrophobic fractions, and the proteins are separated as desired. In a preferred embodiment of the invention, the denatured HOXB4H protein is subjected to a centrifugal speed of about 1000 to about 2500 g/min, and is successively replaced by 5 to 10 centrifugation to obtain a low to high concentration. a solution of a macromolecular hydrophobic substance such as cyclodextrin, which removes the high-k water molecule, and refolds the denatured HOXB4H protein into a natural form. (Native form) ° [Embodiment

8 TBH03-P060009-TW 1311562 本發明將詳細描述特殊的具體實施例。這些具體實施 例經由發明解釋提供,並非意欲用以限制本發明。在發明 的範圍及精神内,本發明存在傾向於包括這些及其他變更 及變動。 實施例1. 以10K centricon對變性H0XB4H蛋 白操作去鹽 本實施例所使用之變性蛋白質為 φ H0XB4H,其大量製造及純化方法經描述於相關 申請案094122467中。 將新的 1 OK centricon ( 50 ml or 1 5 ml)濃縮 管分別加入(1 〇ml or 3 ml)二次水並以離心3〇〇〇 rpm, l〇mins,去除上下層二次水以進行前處 理。將含有變性HOXB4H蛋白的高鹽樣品以1 :4 (蛋白溶液1,D-PBS-T 4混和)與D-PBS-T (含 有0 1% Triton X-100之兩倍磷酸鹽緩衝溶液)混 合,將所成之混合液加入已經前處理之濃縮管 中,離心3000 rpm ’ 1 〇 mins,藉此以80%速率 • 將蛋白變性鹽類Buffer置換至d-PBS-T緩衝 液’以結合HOXB4H蛋白的疏水性(Hydrophobic) 區域。 接著以1000〜2500 g/min離心速度,依序 將經脫鹽之樣品缓衝液置換為含i mM、2mM、 3niM、4mM 及 5mM β-ί衣糊精(beta_cyclodextrin) 存在D-PBS緩衝液之溶液,其中於各離心速度下 以每種濃度置換離心兩次,最後再以D - P B S置換 buffer ’將以各離心速率離心得之蛋白溶液,藉 由利用尚濃度(30 °/〇BSA加90% glycerol)以1:58 TBH03-P060009-TW 1311562 The present invention will describe in detail specific embodiments. These specific examples are provided by way of illustration of the invention and are not intended to limit the invention. The present invention is intended to embrace such modifications and alternatives and modifications. Example 1. Desalting of denatured HOXB4H protein by 10K centricon The denatured protein used in this example was φ H0XB4H, a method for which it was extensively manufactured and purified, as described in the related application 094,122,467. Add a new 1 OK centricon (50 ml or 1 5 ml) concentrator to (1 〇ml or 3 ml) of secondary water and centrifuge 3 rpm, l〇mins to remove the upper and lower secondary water. Pre-processing. Mix high-salt samples containing denatured HOXB4H protein with 1:4 (protein solution 1, D-PBS-T 4 mixed) with D-PBS-T (double phosphate buffer solution containing 0 1% Triton X-100) Add the resulting mixture to the pre-treated concentrate tube and centrifuge 3000 rpm '1 〇mins to replace the protein denatured salt Buffer to d-PBS-T buffer at 80% rate to bind HOXB4H The hydrophobic (Hydrophobic) region of the protein. Then, the desalted sample buffer was sequentially replaced with a solution containing i mM, 2 mM, 3 niM, 4 mM, and 5 mM β-cyclodextrin (beta-cyclodextrin) in the presence of D-PBS buffer at a centrifuge rate of 1000 to 2500 g/min. In which the centrifugation was performed twice at each concentration, and then the buffer was replaced with D-PBS. The protein solution was centrifuged at each centrifugation rate, by using the concentration (30 ° / 〇 BSA plus 90%). Glycerol) at 1:5

TBH03-P060009-TW 9 .1311562 (蛋白溶液)與蛋白溶液混合後, 3白/5%說加15%—二存保於存二: /水相。 人 實施例2·經純化H0XB4H蛋白之再折疊評估 ,評估H0XB4H蛋白經本發明之蛋白去鹽 ^折疊方法後,可再折疊進入細胞核中之情形二 藉由TAT將蛋白輸送至細胞内,其被攜帶蛋 白’必須要以變性狀態或接近於變性狀態以利蛋 • 白進入細胞,因TAT媒介進入的方式,並非如傳 統蛋白進入方式,是藉由能量或有特定通道進 入,TAT媒介進入是首先帶正電的tat與帶負電 的細胞磨接觸後,被攜帶蛋白以直鍊狀^接穿過 細胞膜’過份折疊的蛋白將,因無法解開成為直鍊 狀而導致無法進入細胞(請參見,TATSteven R.TBH03-P060009-TW 9 .1311562 (protein solution) mixed with the protein solution, 3 white / 5% said to add 15% - two deposits in the second: / water phase. Human Example 2. Evaluation of the refolding of the purified H0XB4H protein, and evaluation of the HOXB4H protein by the protein desalting method of the present invention, which can be refolded into the nucleus. The protein is transported into the cell by TAT, which is carried. The protein 'must be in a denatured state or close to a denatured state to facilitate the egg to enter the cell. Because the TAT medium enters the way, it is not like the traditional protein entry mode. It is entered by energy or a specific channel. The TAT media entry is the first one. When the positively charged tat is in contact with a negatively charged cell mill, the protein that is carried by the protein is crossed in a straight line through the cell membrane. The protein that is over-folded cannot be unblocked and becomes incapable of entering the cell (see, TATSteven R.

Schwarze, Keith A. Hruska 與 Steven F· Dowdy,Schwarze, Keith A. Hruska and Steven F. Dowdy,

Trends in cell biology 10,290-295 ) > 遂取分另以, 不同離心 G 值(500g、 750g、 l〇〇〇g、 l25〇g、 1500g、1750g、2000g、2250g 及 2500g)進行如 • 實施例1所述之PBS-T置換所得的蛋白質樣本, 利用西方墨點法偵測HOXB4H蛋白蛋白是否具 有進入細胞核内能力。將2 9 3 T細胞以1 0公分培 養皿培養,至達到1 〇6細胞後,於培養皿中加入 最終濃度為1 5 nM以上述各種不同離心條件處理 後之TAT-HOXB4,於k集後,以D-PBS漂洗Trends in cell biology 10,290-295 ) > Differently, different centrifugal G values (500g, 750g, l〇〇〇g, l25〇g, 1500g, 1750g, 2000g, 2250g and 2500g) were carried out as in the example The protein sample obtained by the PBS-T replacement described above was used to detect whether the HOXB4H protein protein has the ability to enter the nucleus by Western blotting. Twenty-three T cells were cultured in a 10 cm culture dish to reach 1 〇6 cells, and TAT-HOXB4 was added to the culture dish at a final concentration of 15 nM under various centrifugation conditions as described above. Rinse with D-PBS

(1000g 離心 5min)後,以 RIPA ( Radio Immunoprecipitation Assay buffer; 50mM Tris pH7.5, 150mM NaCl,lOmM EDTA,1% NP-40,0.1% SDS,ImM PMSF)抽取蛋白,接著於進行電泳後轉潰至NCAfter centrifugation (1000 g for 5 min), the protein was extracted with RIPA (Radio Immunoprecipitation Assay buffer; 50 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% NP-40, 0.1% SDS, 1 mM PMSF), followed by electrophoresis and then collapsed. To NC

10 TBH03-P060009-TW *1311562 膜上,以西方墨點法偵測ΗΟχΒ4Η蛋白之存在。 其中所使用之一級抗體為anti_His tag抗體(購 自Sigma)’二級抗體為anti-mouseigG抗體(購 自Sigma),且皆於37°C下作用2小時。 結果列示於圖1 ’其中以C為293T參考細 胞’作為negative control陰性對照組,p為經大 量純化後之變性蛋白,作為陽性對照組。由結果 可知在適當條件下,變性H0XB4H蛋白可藉本方 法賦予活性。10 TBH03-P060009-TW *1311562 On the membrane, the presence of ΗΟχΒ4Η protein was detected by Western blotting. The primary antibody used was an anti-His tag antibody (purchased from Sigma), and the secondary antibody was an anti-mouseigG antibody (purchased from Sigma), and both were allowed to act at 37 ° C for 2 hours. The results are shown in Fig. 1 'where C is a 293T reference cell' as a negative control negative control group, and p is a greatly purified denatured protein as a positive control group. From the results, it was found that the denatured HOXB4H protein can be imparted by the method under appropriate conditions.

【圖式簡單說明】 第一圖為利用西方墨點法偵測H0XB4H蛋 白蛋白是否進入細胞核内之結果。其中C為293T 參考細胞;Lane 1至9表示分別於500g、750g、 lOOOg、1 250g > 1 500g ' 1 750g、2000g、2250g 及25 00g之離心速率下,以1 mM、2mM、3mM、 4mM及5mM之β-環糊精溶液進行PBS-T置換, .以各濃度皆離心2次;Lane 10表示於2000g之 • 離心速率下,僅以5mM之β-環糊精溶液離心10 次;Ρ為經大量純化後之ΗΟΧΒ4Η變性蛋白。[Simple description of the figure] The first picture shows the results of using Western blotting to detect whether H0XB4H protein enters the nucleus. Wherein C is a 293T reference cell; Lanes 1 to 9 represent 1 mM, 2 mM, 3 mM, 4 mM at a centrifuge rate of 500 g, 750 g, 1000 g, 1 250 g > 1 500 g '1 750 g, 2000 g, 2250 g, and 25 00 g, respectively. And 5 mM β-cyclodextrin solution was subjected to PBS-T replacement, and centrifuged twice at each concentration; Lane 10 showed that it was centrifuged only 10 times with 5 mM β-cyclodextrin solution at a centrifuge rate of 2000 g; It is a Η4Η denatured protein after extensive purification.

11 TBH03-P060009-TW11 TBH03-P060009-TW

Claims (1)

Ϊ311562 0月(Μ修浼)i 、申請專利範圍: =^用於將經親和性管柱純化之變性蛋白去 ^與再折疊之方法,其包含: 匕1含有經親和性管柱大量純化且存在變 件下之所欲變性蛋白質之溶液與含有選 Tm〇n χ_100或tween_20的高度疏水性分 子之溶液以1:3至1 :5之混合比例混人; 將該混合液通過蛋白濃縮管柱或σ蛋白超 據膜於1000至3000 g/min之離心速度下離心 5 _ 1 0分鐘進行快速去鹽;及 (c)將經步驟(b)去鹽之蛋白溶液於1〇〇〇〜 2 5 〇〇 g/min之離心速度下以漸進離心置換方 式進行5-10次離心除去該兩度疏水分子而使 s亥變性蛋白再折疊,其中該漸進離心置換係 以從低濃度至高濃度之 β-環糊精 (β-cyclodextrin)溶液依序將該高度疏水分 子置換出。 2 ·根據申請專利範圍第1項之方法,其中該變性 蛋白為ΗΟΧΒ4Η變性蛋白。 ' 3.根據申請專利範圍第1項之方法,其中該漸進 每隹心置換為於1000〜2500 g/min之離心速度 下依序將經脫鹽之樣品緩衝液置換為含 ImM、2mM、3mM、4mM 及 β-環糊精存 在D - P B S缓衝液之溶液。 12 TBH03-P060009-TWΪ311562 0 (Μ修浼) i , the scope of patent application: = ^ method for the purification and refolding of the denatured protein purified by the affinity column, comprising: 匕 1 containing a large number of purified and affinity column a solution of the desired denatured protein under the variation and a solution containing a highly hydrophobic molecule selected from Tm〇n χ100 or tween_20 are mixed in a mixing ratio of 1:3 to 1:5; the mixture is passed through a protein concentrating column Or σ protein super-film is centrifuged at a centrifugal speed of 1000 to 3000 g / min for 5 _ 10 minutes for rapid desalting; and (c) step (b) desalted protein solution at 1 〇〇〇 2 5 离心g/min at a centrifugation speed for 5-10 centrifugation to remove the two-degree hydrophobic molecule to refold the s-denatured protein, wherein the progressive centrifugation is performed from a low concentration to a high concentration of β The cyclodextrin (β-cyclodextrin) solution sequentially displaces the highly hydrophobic molecule. 2. The method of claim 1, wherein the denatured protein is a ΗΟΧΒ4Η denatured protein. 3. The method of claim 1, wherein the progressive centrifugation is performed by sequentially replacing the desalted sample buffer with ImM, 2 mM, 3 mM at a centrifugation speed of 1000 to 2500 g/min. A solution of 4 mM and β-cyclodextrin in D-PBS buffer was present. 12 TBH03-P060009-TW
TW95116399A 2006-05-09 2006-05-09 One step rapid desalting and protein refolding process TWI311562B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW95116399A TWI311562B (en) 2006-05-09 2006-05-09 One step rapid desalting and protein refolding process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW95116399A TWI311562B (en) 2006-05-09 2006-05-09 One step rapid desalting and protein refolding process

Publications (2)

Publication Number Publication Date
TW200742744A TW200742744A (en) 2007-11-16
TWI311562B true TWI311562B (en) 2009-07-01

Family

ID=45072447

Family Applications (1)

Application Number Title Priority Date Filing Date
TW95116399A TWI311562B (en) 2006-05-09 2006-05-09 One step rapid desalting and protein refolding process

Country Status (1)

Country Link
TW (1) TWI311562B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124377B2 (en) 2008-03-04 2012-02-28 Taiwan Advance Bio-Pharm Inc. Method of producing TAT-HOXB4H

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124377B2 (en) 2008-03-04 2012-02-28 Taiwan Advance Bio-Pharm Inc. Method of producing TAT-HOXB4H
US8222207B2 (en) 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
US8222206B2 (en) 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
US8450458B2 (en) 2008-03-04 2013-05-28 Taiwan Advance Bio-Pharm Inc. Recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo

Also Published As

Publication number Publication date
TW200742744A (en) 2007-11-16

Similar Documents

Publication Publication Date Title
Vuckovic et al. Membrane proteomics by high performance liquid chromatography–tandem mass spectrometry: Analytical approaches and challenges
Li et al. Predictive recognition of native proteins by cucurbit [7] uril in a complex mixture
JP6385374B2 (en) Substances and methods for removing endotoxins from protein formulations
Shenkarev et al. Lipid–protein nanodiscs promote in vitro folding of transmembrane domains of multi-helical and multimeric membrane proteins
Bjørkskov et al. Purification and functional comparison of nine human Aquaporins produced in Saccharomyces cerevisiae for the purpose of biophysical characterization
JPH0660198B2 (en) How to collect protein
Alvarez‐Guerra et al. Ionic liquid‐based three phase partitioning (ILTPP) systems for whey protein recovery: ionic liquid selection
US20230348863A1 (en) Purification matrices comprising aav-binding polypeptides and methods of using the same
US20220010288A1 (en) Protein-based purification matrices and methods of using the same
Coleman et al. Filter-aided sample preparation (FASP) for improved proteome analysis of recombinant chinese hamster ovary cells
AU2011317021A1 (en) Methods for processing inclusion bodies
Vagenende et al. Allantoin as a solid phase adsorbent for removing endotoxins
JP5271354B2 (en) Method for separating recombinant proteins in an aqueous two-phase system
Knudsen et al. On-line solid-phase extraction–capillary electrophoresis for enhanced detection sensitivity and selectivity: application to the analysis of metallothionein isoforms in sheep fetal liver
TWI311562B (en) One step rapid desalting and protein refolding process
Smith et al. Hydroxyapatite chromatography of phage-display virions
CN109182281B (en) Method and kit for treating adeno-associated virus
Wang The role of nonhistone chromosomal proteins in the interaction of prostate chromatin with androgen· receptor complex
Rocha Aqueous two‐phase systems and monolithic chromatography as alternative technological platforms for virus and virus‐like particle purification
WO2021120900A1 (en) Method for preparing recombinant human nerve growth factor
Marchel et al. Application of aqueous biphasic systems extraction in various biomolecules separation and purification: advancements brought by quaternary systems
Chakraborty et al. Protein purification by ion exchange chromatography
Plucinsky et al. Efficient solubilization and purification of highly insoluble membrane proteins expressed as inclusion bodies using perfluorooctanoic acid
Smyth et al. Eukaryotic expression and purification of recombinant extracellular matrix proteins carrying the Strep II tag
Balduino et al. Refolding by high pressure of a toxin containing seven disulfide bonds: Bothropstoxin-1 from Bothrops jararacussu